5-Androstenediol Ameliorates Pleurisy, Septic Shock, and Experimental Autoimmune Encephalomyelitis in Mice
Author(s) -
Ferdinando Nicoletti,
Dominick L. Auci,
Katia Mangano,
J R Flores-Riveros,
Sonia L. Villegas,
James M. Frincke,
Christopher L. Reading,
Halina Offner
Publication year - 2010
Publication title -
autoimmune diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.681
H-Index - 32
eISSN - 2090-0422
pISSN - 2090-0430
DOI - 10.4061/2010/757432
Subject(s) - medicine , algorithm , septic shock , sepsis , proinflammatory cytokine , androstenediol , experimental autoimmune encephalomyelitis , inflammation , immunology , mathematics , hormone , androstenedione , androgen
Androstenediol (androst-5-ene-3 β ,17 β -diol; 5-AED), a natural adrenal steroid, has been shown to suppress experimental autoimmune encephalomyelitis (EAE) in female SJL/J mice. We here report that 5-AED limits inflammation and proinflammatory cytokines including TNF α in murine models of carrageenan-induced pleurisy and lippopolysaccaride- (LPS) induced septic shock. 5-AED binds to and transactivates sex steroid receptors with the same general rank order of potency (ER β > ER α ≫ AR). 5-AED provides benefit in EAE in a dose-dependent fashion, even when treatment is delayed until onset of disease. The minimally effective dose may be as low as 4 mg/kg in mice. However, benefit was not observed when 5-AED was given in soluble formulation, leading to a short half-life and rapid clearance. These observations suggest that treatment with 5-AED limits the production of pro-inflammatory cytokines in these animal models and, ultimately, when formulated and administered properly, may be beneficial for patients with multiple sclerosis and other Th1-driven autoimmune diseases.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom